On Monday, British drug manufacturer AstraZeneca announced that the COVID-19 vaccine developed by the University of Oxford triggered an immune response in both young adults and older people.
Older individuals have a weaker immune system than younger people, meaning that an immune response in the elderly is great news for those that have had to shelve their regular schedules and stay isolated at home for months.
Previously, the Financial Times said that the Oxford University COVID-19 vaccine produced T-cells and protective antibodies in the elderly.
In April, AstraZeneca took on the job of producing and scheduling human trials for the Oxford University vaccine known as AZD1222.
According to AstraZeneca CEO Pascal Soriot, the vaccine is expected to protect an individual for a year.
The United States is currently leading global COVID-19 cases with over 8.8 million infections and 230,510 fatalities, although India follows closely behind with 7.9 million cases and 119,030 deaths. As for the third-highest case toll and death toll, Brazil follows with 5.3 million cases and 157,163 deaths, Russia with 1.5 million cases and 26,269 deaths, and Spain with 1.1 million infections and 26,269 deaths.
The novel coronavirus was first discovered in Wuhan, Hubei, China, on Dec. 31, 2019, and has infected more than 43 million individuals worldwide, resulting in over 1.3 million fatalities across 188 countries and territories.
The Panthera Post 